DYAX: Dyax Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp.

DYAX 38.41

0.0%

Jan 25 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	6/2/2004 9:50:56 AM
	of 197

Dyax Corp. and Genzyme Enter Into License Agreement for Discovery of Therapeutic Antibodies Wednesday June 2, 7:30 am ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 2, 2004--Dyax Corp (Nasdaq: DYAX - News) announced today that it has granted a non-exclusive license to its proprietary antibody phage display libraries to Genzyme Corporation for the discovery of human antibodies, initially for use in the research field and with options for therapeutic antibodyproduct development. Under the terms of the agreement, Dyax will receive payment that includes an upfront technology license fee, clinical milestone payments, and royalties on net sales of products that may result from Genzyme's use of the Dyax libraries. Genzyme also has the option to have Dyax perform funded research on its behalf. The agreement provides Genzyme with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology. ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next